|
|
Volumn 61, Issue SUPPL. 2, 2001, Pages 31-36
|
|
Dose scheduling - Herceptin®
a
|
|
Author keywords
3 weekly; Combination therapy; Herceptin ; Metastatic breast cancer; Pharmacokinetics; Single agent; Subcutaneous
|
|
Indexed keywords
CAPECITABINE;
CISPLATIN;
DOXORUBICIN;
ETOPOSIDE;
FLUOROURACIL;
METHOTREXATE;
PACLITAXEL;
TAXANE DERIVATIVE;
THIOTEPA;
TRASTUZUMAB;
VINBLASTINE;
ANTINEOPLASTIC ACTIVITY;
AREA UNDER THE CURVE;
BREAST CARCINOMA;
CONFERENCE PAPER;
DOSE RESPONSE;
DOSE TIME EFFECT RELATION;
DRUG EFFECT;
DRUG SAFETY;
HUMAN;
IN VITRO STUDY;
MONOTHERAPY;
PREDICTION;
PRIORITY JOURNAL;
ABDOMINAL MUSCLES;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
AREA UNDER CURVE;
BREAST NEOPLASMS;
CISPLATIN;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
DEOXYCYTIDINE;
DRUG ADMINISTRATION SCHEDULE;
DRUG ANTAGONISM;
DRUG EVALUATION, PRECLINICAL;
DRUG SYNERGISM;
FEASIBILITY STUDIES;
FEMALE;
FLUOROURACIL;
HALF-LIFE;
HAPLORHINI;
HUMANS;
INFUSIONS, INTRAVENOUS;
INJECTIONS, SUBCUTANEOUS;
METHOTREXATE;
NEOPLASM METASTASIS;
PACLITAXEL;
SAFETY;
TREATMENT OUTCOME;
VINBLASTINE;
XENOGRAFT MODEL ANTITUMOR ASSAYS;
|
|
EID: 0034760145
PISSN: 00302414
EISSN: None
Source Type: Journal
DOI: 10.1159/000055399 Document Type: Conference Paper |
|
Times cited : (47)
|
|
References (27)
|
